Literature DB >> 7908057

Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog.

M Berlan1, J Galitzky, A Bousquet-Melou, M Lafontan, J L Montastruc.   

Abstract

Beta-3 adrenergic agonist administration decreases arterial blood pressure in the dog as previously shown. The putative presence of beta-3 adrenoceptors in peripheral microvascular muscle was studied in dogs through measurement of cutaneous blood flow and skin temperature changes. Experiments were carried out in normal and sinoaortic denervated dogs (i.e., animals deprived of baroreceptor pathways). In normal dogs, the infusion of 0.4 nmol/kg/min of 4-[-[(2-hydroxy-(3-chlorophenyl)ethyl)-amino]propyl] phenoxyacetate (BRL 37344) or (R,R-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3- benzodioxole-2,2-dicarboxylate (CL 316243) (two selective beta-3 adrenoceptor agonists), or 8 nmol/kg/min of 4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2-one (CGP 12177) (a beta-1/beta-2 adrenergic antagonist also reported to act as an agonist for the beta-3 adrenoceptor) induced an increase in heart rate and cutaneous blood flow (evaluated in the internal part of the ear) and a decrease in blood pressure. The skin and the buccal mucous membrane became purplish. The infusion of (-)-isoproterenol (0.4 nmol/g/min), a dose known to stimulate preferentially beta-1/beta-2 adrenoceptors, or sodium nitroprusside (12 micrograms/kg/min) increased heart rate and decreased blood pressure, but reduced cutaneous blood flow. In sinoaortic denervated dogs, similar effects on cutaneous blood flow and blood pressure were observed. However, in these animals, heart rate remained unchanged whatever the infused drug. BRL 37344 (but not isoproterenol) increased cutaneous temperature in normal dogs. This study suggests that beta-3 adrenoceptors exist in canine cutaneous vascular smooth muscles and that their stimulation induces vasodilatation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908057

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

2.  Increased Ca2+ sensitivity and protein expression of SERCA 2a in situations of chronic beta3-adrenoceptor deficiency.

Authors:  Christoph Ziskoven; Sabrina Grafweg; Birgit Bölck; Rudolf J Wiesner; Maria Jimenez; Jean-Paul Giacobino; W Bloch; Robert H G Schwinger; Klara Brixius
Journal:  Pflugers Arch       Date:  2006-09-22       Impact factor: 3.657

3.  Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Authors:  Y L Liu; M A Cawthorne; M J Stock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta.

Authors:  J N Trochu; V Leblais; Y Rautureau; F Bévérelli; H Le Marec; A Berdeaux; C Gauthier
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Role of potassium channels and nitric oxide in the relaxant effects elicited by beta-adrenoceptor agonists on hypoxic vasoconstriction in the isolated perfused lung of the rat.

Authors:  J P Dumas; F Goirand; M Bardou; M Dumas; L Rochette; C Advenier; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium.

Authors:  M Bardou; C Loustalot; J Cortijo; B Simon; E Naline; M Dumas; S Esteve; T Croci; P Chalon; R Frydman; P Sagot; L Manara; E J Morcillo; C Advenier
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

8.  Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors.

Authors:  B Malinowska; E Schlicker
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue.

Authors:  P Barbe; L Millet; J Galitzky; M Lafontan; M Berlan
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium.

Authors:  C Pott; K Brixius; A Bundkirchen; B Bölck; W Bloch; D Steinritz; U Mehlhorn; R H G Schwinger
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.